Eris Lifesciences is planning to acquire part of the dermatology portfolio of Dr Reddy's Laboratories by way of acquisition of nine trademarks along with their applicable line extensions (collectively referred to as Brands) for consideration of Rs 275 crore. The transaction helps augment and expand the cosmetic dermatology business of the company by way of expansion in the product offerings. The Transaction is to stand completed on or before March 31, 2023.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
